Intellia Therapeutics

Intellia Therapeutics

Intellia Therapeutics (NASDAQ: NTLA) is a clinical-stage biotechnology company leading the development of CRISPR/Cas9 technologies for gene editing and gene therapy. Founded in 2014 as a spinout from Novartis, Intellia is headquartered in Cambridge, Massachusetts.

Overview

Intellia Therapeutics

Intellia Therapeutics (NASDAQ: NTLA) is a clinical-stage biotechnology company leading the development of CRISPR/Cas9 technologies for gene editing and gene therapy. Founded in 2014 as a spinout from Novartis, Intellia is headquartered in Cambridge, Massachusetts.

Overview

| Attribute | Details | [@ntla2001]
|-----------|---------| [@regeneron2023]
| Founded | 2014 | [@pipeline2024]
| Headquarters | Cambridge, Massachusetts, USA | [@vivo2020]
| IPO | NASDAQ: NTLA (2018) |
| Market Cap | ~$4B (2024) |
| Employees | ~600 |
| Website | intelliatx.com |

Technology Platform

CRISPR/Cas9 with LNP Delivery

Intellia specializes in lipid nanoparticle (LNP) delivery for in vivo gene editing:

• Cas9: Proprietary Cas9 formulations
• Guide RNA: Synthetic single guide RNAs
• Delivery: Proprietary LNPs for tissue-specific targeting
• Advantages: Non-viral, repeatable dosing

Platform Capabilities

Pipeline

Clinical Programs

| Program | Indication | Target | Status |
|---------|------------|--------|--------|
| NTLA-2001 | Transthyretin (ATTR) amyloidosis | TTR | Phase 3 |
| NTLA-2002 | Hereditary angioedema | KLKB1 | Phase 1/2 |
| NTLA-3001 | Alpha-1 antitrypsin deficiency | SERPINA1 | Phase 1 (IND cleared) |

Neurological Disease Programs

Amyotrophic Lateral Sclerosis (ALS)

• Target: SOD1 gene mutations
• Approach: Knockout of mutant SOD1
• Status: Discovery
• Partner: Regeneron

Alzheimer's Disease

• Target: Amyloid-related genes
• Approach: Gene silencing
• Status: Discovery

Parkinson's Disease

• Target: GBA1 and other risk genes
• Approach: Correct or modulate expression
• Status: Discovery

Autonomic Dysfunction and GBA1 in Parkinson's Disease

Intellia's Parkinson's disease program targeting [GBA1](/genes/gba1) is particularly relevant for autonomic dysfunction:

GBA1 and Autonomic Symptoms

Heterozygous GBA1 mutations are the most common genetic risk factor for PD and are associated with:

• Earlier Onset: GBA-PD patients develop symptoms ~5 years earlier
• More Severe Autonomic Dysfunction: Higher prevalence of orthostatic hypotension, constipation, and urinary dysfunction
• Faster Progression: More rapid decline in both motor and non-motor symptoms

Intellia's CRISPR-based approach offers potential benefits:

• Gene Correction: Potentially restore glucocerebrosidase activity, improving lysosomal function
• Autonomic Neuron Protection: Protect the [dorsal motor nucleus of the vagus](/cell-types/dorsal-motor-nucleus-vagus) and [enteric neurons](/cell-types/enteric-neurons-pd) from alpha-synuclein pathology
• Disease Modification: Address the root cause rather than just symptoms

| Target | Autonomic Relevance |
|--------|---------------------|
| GBA1 | Lysosomal dysfunction, alpha-synuclein accumulation |
| Additional risk genes | May be identified for autonomic-specific targeting |

Clinical Progress

| Year | Milestone |
|------|-----------|
| 2014 | Founded as Novartis spinout |
| 2018 | IPO on NASDAQ |
| 2020 | First in vivo CRISPR data in humans (NTLA-2001) |
| 2021 | Positive Phase 1 data for NTLA-2001 |
| 2023 | Regeneron partnership ($400M upfront) |
| 2024 | Phase 3 enrollment for NTLA-2001 |

Key Partnerships

Regeneron Pharmaceuticals

• Focus: Neurological diseases, CNS delivery
• Programs: ALS, Alzheimer's, others
• Deal Value: $400M upfront, $2B+ in milestones

Novartis

• Focus: Original LNP technology license
• Programs: Various in vivo programs

Competitive Landscape

| Company | Technology | Key Differentiator |
|---------|------------|---------------------|
| CRISPR Therapeutics | Ex vivo editing | First FDA-approved CRISPR therapy |
| Editas Medicine | In vivo CRISPR | CRISPR/Cas12a |
| Beam Therapeutics | Base editing | Precision editing |
| Intellia | LNP delivery | In vivo systemic delivery |

NTLA-2001: First Systemic CRISPR

NTLA-2001 is the first systemically delivered CRISPR gene-editing therapy to show clinical activity:

• Target: TTR protein (transthyretin)
• Results: Up to 89% reduction in TTR protein
• Dosing: Single intravenous infusion
• Durability: Sustained reduction for 12+ months

NeuroWiki Cross-References

• CRISPR Gene Editing
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration) Lipid Nanoparticles
• Companies Index
• [RNAi Therapeutics](/genes/th)
• [CRISPR-Cas9](/proteins/spr)
• [Gene Therapy](/therapeutics/gene-therapy)
• [Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
• [Parkinson's Disease Pipeline Companies](/companies/pd-neurogenesis-companies)
• [GBA1 Gene](/genes/gba1)
• [Autonomic Dysfunction in Parkinson's Disease](/diseases/autonomic-dysfunction-in-corticobasal-syndrome)
• [Enteric Neurons](/cell-types/enteric-neurons-pd)
• [Dorsal Motor Nucleus of the Vagus](/cell-types/dorsal-motor-nucleus-vagus)

External Links

• [Intellia Therapeutics Website](https://intelliatx.com)
• [Intellia Therapeutics Pipeline](https://intelliatx.com/pipeline/)

References